Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis teams up with Medicines for Malaria Venture

Sanofi-aventis teams up with Medicines for Malaria Venture

24th October 2008

Sanofi-aventis, the Paris-listed global pharmaceutical company, has announced the beginning of a joint partnership with not-for-profit organisation Medicines for Malaria Venture.

The companies aim to speed up development and research of new malaria treatments by sharing information regarding Sanofi-aventis’ drugs portfolio.

Working groups for the review of these products are also to be set up and a antimalarials research programme is intended to screen a “very large number” of candidate compounds.

Sanofi-aventis senior vice-president of research and development Marc Cluzel explained why the partnership was important for the ongoing discoveries of malaria medicines.

“[It] will help us stay ahead in the race against parasites that will sooner or later develop resistances to existing treatments,” he said.

“This new partnership will enable us to mobilize each organisation’s expertise, resources and know-how.”

Medicines for Malaria Venture was originally formed in 1999 and currently counts approximately 40 products in its portfolio.

Malaria is spread via infected female mosquitos and is caused by the certain species of the parasite plasmodium.

Between 300 million and 500 million cases are estimated to occur every year, with between 1.5 million and 2.7 million of these proving fatal, according to statistics reported by Net Doctor.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.